Cholangiocarcinoma is often diagnosed late — but 40–50% of patients may have actionable mutations

In our latest podcast, we explore the case for early molecular testing and the role of the MDT in expanding treatment options | 🎧 Listen: t.ly/J_Wv2
#oncology #MedEd #BTC #BillaryTractCancers #OncSky